Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159469 · ClinicalTrials.gov registry record · Phase 3
Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism
A Phase 3 study, sponsored by Antares Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT02159469 is a Phase 3 study that has completed, run by Antares Pharma. The registered enrollment target is 150 participants.
The verdict
NCT02159469, a Phase 3 study, has completed, sponsored by Antares Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
Evaluation of efficacy and safety of testosterone enanthate administered subcutaneously using an auto-injector
Interventions
- COMBINATION_PRODUCT Testosterone enanthate auto-injector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02159469
The ClinicalTrials.gov registry entry for NCT02159469 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Antares Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Testosterone enanthate auto-injector is the first listed.
NCT02159469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02159469 about?
NCT02159469 is a clinical study titled "Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism". Evaluation of efficacy and safety of testosterone enanthate administered subcutaneously using an auto-injector
What is the current status of trial NCT02159469?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2014-07. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02159469?
The interventions under investigation include: Testosterone enanthate auto-injector (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT02159469?
This trial is sponsored by Antares Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.